Gordian Biotechnology focuses on developing treatments for age-related diseases through drug discovery. The company uses advanced technologies to create models that accurately reflect the complexities of aging, which helps in testing therapies in conditions similar to those in humans. This method increases the chances of success in clinical trials. Gordian Bio primarily collaborates with pharmaceutical companies, research institutions, and healthcare providers, generating revenue through partnerships and licensing agreements. Their goal is to extend healthy human lifespan by addressing the underlying causes of age-related diseases. They utilize animal models, like fruit flies, to study aging and test new therapies, which enhances the reliability of their research. The team consists of experts in gene therapy and genome engineering, and their work has been recognized at major industry conferences.

Founders Fund

Gigafund

Arctica Ventures

Longevity Fund

ATHOS Venture

Fifty Years

Thomas Ebeling

Biotechnology

Healthcare

Gordian Biotechnology

High-throughput in vivo screening platform can test hundreds of gene therapies simultaneously in animals closely mirroring human biology.

Gordian launches with $60m and platform that predicts outcomes in age-related diseases

Gordian Biotechnology launched with $60m in venture capital, introducing a high-throughput in vivo screening platform for age-related diseases. Using "patient avatars" like horses and monkeys, the platform tests hundreds of gene therapies simultaneously, achieving 80% predictive accuracy in proof-of-concept experiments. This method could significantly streamline drug discovery and development for age-related conditions.

Gordian Launches with $60M for Gene Therapy

Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies. The results of these ex vivo studies matched screen predictions with 80% accuracy, and several hits progressed to additional testing and optimization. Gordian presented these findings at the Osteoarthritis Research Society International (OARSI) World Congress last week.In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH). The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.Today, Gordian is completing in vivo screens of thousands of novel single and multi-target therapies across four indications in highly representative animal models across multiple species."Gordian leverages recent advancements in single-cell sequencing and gene therapy to discover and predict what drugs will be successful in a way that would have been inconceivable just five years ago," said co-founder and CEO Francisco LePort. "Our ultimate goal is to help people wake up every day, more capable than the one before."The first and only platform of its kindScreening in vivo lets Gordian run the equivalent of hundreds of preclinical experiments in a matter of months and at a small fraction of the cost of traditional preclinical studies. Thus, enormous amounts of in vivo data are obtained at the beginning of the discovery process in animal models that would otherwise be impractical to use, allowing only the most efficacious therapeutics to move into development and clinical trials.The Gordian platform consists of three proprietary components working in concert:Patient Avatars™ are animal models with biology more representative of human patients than those typically used, such as horses for OA and monkeys for MASH

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform To Discover Therapies And Better Predict Human Outcomes For Age-Related Diseases

Gordian Biotechnology introduces high-throughput in vivo screening platform to discover therapies and better predict human outcomes for age-related diseases.

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Biotech startup focused on age-related diseases

Gordian Biotechnology

Biotech startup focused on age-related diseases

Gordian Biotechnology

Biotech startup focused on age-related diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes Gordian Biotechnology unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Gordian Biotechnology is Hiring for 0 Jobs on Simplify!